🕵️ VERA Therapeutics, Inc. ($VERA)
SEC insider & ownership activity, last 12 months · CIK 1831828 · every row links its SEC filing
Over the last 12 months insiders sold $7.7M against $250K of open-market buying. Marshall Fordyce sold $5.1M through a 10b5-1 trading plan in 12 lots (Feb–Jul). T. ROWE Price Associates, Inc. trimmed 7.7% → 6.4%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $250K (1 lots) · 8 sellers, $7.7M (23 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Marshall Fordyce | 0 | – | 12 | $5.1M | Jul 7, 2026 |
| William Donald Turner | 0 | – | 4 | $1.4M | Feb 23, 2026 |
| Joseph R. Young | 0 | – | 2 | $567K | Feb 23, 2026 |
| Patrick G. Enright | 1 | $250K | 0 | – | Dec 11, 2025 |
| Sean Grant | 0 | – | 1 | $208K | Feb 23, 2026 |
| David L Johnson | 0 | – | 1 | $108K | Feb 23, 2026 |
| Jason S. Carter | 0 | – | 1 | $107K | Nov 21, 2025 |
| Robert Brenner | 0 | – | 1 | $90K | Feb 23, 2026 |
| Laurence Skelton | 0 | – | 1 | $66K | Feb 23, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.9% | 13G | Feb 14, 2025 | filing ↗ | |
| Behzad Aghazadeh | 8.9% | 13G | Feb 14, 2025 | filing ↗ | |
| T. ROWE Price Associates, Inc. | 6.4% | 13G | May 15, 2026 | filing ↗ | |
| DEEP Track Capital, LP | 5.5% | 13G | Mar 11, 2026 | filing ↗ | |
| DEEP Track Biotechnology Master Fund, Ltd. | 5.5% | 13G | Mar 11, 2026 | filing ↗ | |
| David Kroin | 5.5% | 13G | Mar 11, 2026 | filing ↗ | |
| Kynam Capital Management, LP | 5.4% | 13G | Aug 14, 2025 | filing ↗ | |
| Kynam Capital Management GP, LLC | 5.4% | 13G | Aug 14, 2025 | filing ↗ | |
| Yue Tang | 5.4% | 13G | Aug 14, 2025 | filing ↗ | |
| Deerfield MGMT, L.P. | 5.2% | 13G | Jun 11, 2025 | filing ↗ | |
| Deerfield Management Company, L.P. | 5.2% | 13G | Jun 11, 2025 | filing ↗ | |
| Deerfield Partners, L.P. | 5.2% | 13G | Jun 11, 2025 | filing ↗ | |
| James E. Flynn | 5.2% | 13G | Jun 11, 2025 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Marshall Fordyce | $2.8M | Jun 23, 2026 | filing ↗ |
| Marshall Fordyce | $677K | May 12, 2026 | filing ↗ |
| Marshall Fordyce | $1.0M | Apr 14, 2026 | filing ↗ |
| Laurence Skelton | $76K | Feb 23, 2026 | filing ↗ |
| William Donald Turner | $109K | Feb 23, 2026 | filing ↗ |
| Sean Grant | $240K | Feb 23, 2026 | filing ↗ |
| Robert Brenner | $105K | Feb 23, 2026 | filing ↗ |
| David L Johnson | $122K | Feb 23, 2026 | filing ↗ |
| Marshall Fordyce | $698K | Feb 23, 2026 | filing ↗ |
| William Turner | $498K | Dec 15, 2025 | filing ↗ |
| William Turner | $449K | Dec 8, 2025 | filing ↗ |
| William Turner | $372K | Dec 3, 2025 | filing ↗ |
| Jason S. Carter | $108K | Nov 21, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jul 9, 2026 | filing ↗ |
| Other events (8.01) | Jul 7, 2026 | filing ↗ |
| Other events (8.01) | Jun 2, 2026 | filing ↗ |
| Shareholder vote (5.07) | May 21, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 5, 2026 | filing ↗ |
| Earnings (2.02) | Feb 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 26, 2026 | filing ↗ |
| Officer/director changes (5.02) | Dec 16, 2025 | filing ↗ |
| Other events (8.01) | Dec 9, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 9, 2025 | filing ↗ |
| Officer/director changes (5.02) | Nov 25, 2025 | filing ↗ |
| Other events (8.01) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Earnings (2.02) | Nov 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 5, 2025 | filing ↗ |
| Material agreement (1.01) | Aug 5, 2025 | filing ↗ |
| Agreement terminated (1.02) | Aug 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 5, 2025 | filing ↗ |
| Earnings (2.02) | Aug 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 5, 2025 | filing ↗ |